- Conditions
- HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Interventions
- Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure, Docetaxel, Goserelin Acetate, Laboratory Biomarker Analysis, Pertuzumab, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, Whole Breast Irradiation
- Drug · Other · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 731
- States / cities
- Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 6,846
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Migraine, Major Depressive Disorder
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • San Diego, California • Denver, Colorado + 14 more
- Conditions
- Prostate Cancer
- Interventions
- sipuleucel-T, Placebo
- Biological
- Lead sponsor
- Dendreon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 34
- States / cities
- Duarte, California • Loma Linda, California • Rancho Mirage, California + 26 more
- Conditions
- Type-2 Diabetes
- Interventions
- vildagliptin
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2007
- U.S. locations
- 5
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more
- Conditions
- Ulcerative Colitis
- Interventions
- Low Dose MT-1303, High Dose MT-1303, Placebo, MT-1303
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 22
- States / cities
- Chandler, Arizona • Los Angeles, California • Rancho Cucamonga, California + 18 more
- Conditions
- Carcinoma, Non-Squamous Non-Small Cell Lung
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Nab-Paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 723 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 57
- States / cities
- Springdale, Arkansas • Oakland, California • Roseville, California + 52 more
- Conditions
- Influenza
- Interventions
- Nitazoxanide, Placebo
- Drug
- Lead sponsor
- Romark Laboratories L.C.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 34
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 28 more
- Conditions
- Sexual Dysfunctions, Psychological
- Interventions
- Flibanserin, Placebo
- Drug
- Lead sponsor
- Sprout Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 1,090 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 61 more
- Conditions
- Lung Cancer
- Interventions
- smoking cessation intervention, bupropion hydrochloride, nicotine, psychosocial assessment and care
- Behavioral · Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 175
- States / cities
- Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 115 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Otilimab (GSK3196165), csDMARD(s)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,916 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 79
- States / cities
- Anniston, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 63 more
- Conditions
- Obesity or Overweight
- Interventions
- AZD6234, Placebo comparator
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 19 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg
- Drug
- Lead sponsor
- Human Genome Sciences Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 53 more
- Conditions
- Nocturia, Prostatic Hyperplasia
- Interventions
- silodosin
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Laguna Hills, California • San Diego, California + 24 more
- Conditions
- Emphysema
- Interventions
- EBV, Optimal Medical Management
- Device · Other
- Lead sponsor
- Pulmonx Corporation
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
- Conditions
- Myocardial Ischemia, Coronary Arteriosclerosis, Aortic Valve Insufficiency, Mitral Valve Insufficiency
- Interventions
- TP10
- Drug
- Lead sponsor
- Avant Immunotherapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 18
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Gainesville, Florida + 15 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,011 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 57
- States / cities
- Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
- Conditions
- Renal Impairment, Renal Disease, Kidney Disease
- Interventions
- Nitazoxanide
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Miami Lakes, Florida • Orlando, Florida
- Conditions
- Hepatitis C Virus Infection
- Interventions
- VOX, SOF/VEL, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 31
- States / cities
- Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more
- Conditions
- Dementia, Alzheimer's Disease
- Interventions
- [18F]NAV4694
- Drug
- Lead sponsor
- Navidea Biopharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 15
- States / cities
- Sun City, Arizona • La Jolla, California • Fort Myers, Florida + 12 more
- Conditions
- HIV -1 Infection
- Interventions
- TMB-365, TMB-380, Baseline ART
- Drug
- Lead sponsor
- TaiMed Biologics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 7 more
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
- Interventions
- maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 18
- States / cities
- Santa Monica, California • Miami, Florida • Orlando, Florida + 10 more
- Conditions
- Coronavirus, Covid19
- Interventions
- bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,044 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 207
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
- Conditions
- Migraine
- Interventions
- ASY202, Placebo
- Combination Product
- Lead sponsor
- Aspeya, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Lemon Grove, California • Walnut Creek, California + 16 more
- Conditions
- Anaemia
- Interventions
- Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 3,872 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 161
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more